GOOD THERAPEUTICS
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
GOOD THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.goodtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(253) 271-4341
Email Addresses:
[email protected]
Total Funding:
30.2 M USD
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
RiverVest
RiverVest investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series B - Good Therapeutics
3ร5 Partners
3ร5 Partners investment in Series B - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Good Therapeutics
Codon Capital
Codon Capital investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series A - Good Therapeutics
3x5 Partners
3x5 Partners investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Official Site Inspections
http://www.goodtherapeutics.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Good Therapeutics"
Good Therapeutics Company Profile 2024: Valuation, Investors ...
Good Therapeutics is headquartered in Seattle, WA. What is the size of Good Therapeutics? Good Therapeutics has 26 total employees. What industry is Good Therapeutics in? Good โฆSee details»
Good Therapeutics Company Profile - Office Locations ... - Craft
Good Therapeutics is a biotechnology company developing protein drugs that sense biomarkers and respond with therapeutic activity. Its core technology is an algorithm for designing proteins โฆSee details»
Good Therapeutics - Overview, News & Similar companies
Dec 30, 2021 Who is Good Therapeutics. Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs โฆSee details»
Good Therapeutics, Inc. | LinkedIn
Good Therapeutics, Inc. | 3,757 followers on LinkedIn. Systemic delivery, local activity | At Good Therapeutics we are developing protein-based drugs with regulated, context-dependent activity.See details»
Good Therapeutics Company Profile: Overview and Full News โฆ
Good Therapeutics, located in Washington, operates under the brand name Bonum Therapeutics, focusing on developing regulated protein therapeutics using allosteric regulation technology. โฆSee details»
Good Therapeutics - VentureRadar
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. They are developing "context-dependent" protein drugs that sense biomarkers and respond with a โฆSee details»
Roche acquires Good Therapeutics - 2022-09-07 - Crunchbase
Sep 7, 2022 Good Therapeutics Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. Acquiring Organization: โฆSee details»
Good Therapeutics - Company Profile - Tracxn
Jan 6, 2025 Good Therapeutics. has raised a total funding of $37.1M over 3 rounds. Its first funding round was on Nov 2018. What are the most recent funding rounds of Good โฆSee details»
Good Therapeutics - Funding, Financials, Valuation & Investors
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. Search Crunchbase. ... How much funding has โฆSee details»
Good Therapeutics - Products, Competitors, Financials, Employees ...
Good Therapeutics spinout Bonum banks $93 million in Series A. Nov 16, 2022. 16-11-2022 Bonum Therapeutics, a biopharma using allosteric regulation to create conditionally active and โฆSee details»
Good Therapeutics lands $8M to develop protein drugs that
Dec 30, 2021 Good Therapeutics is developing an IL-2-based agent that is active when bound to immune T cells that recognize tumors. The therapeutic binds a target on such cells, PD-1, then โฆSee details»
CASE STUDY: GOOD THERAPEUTICS - RiverVest
Aug 3, 2023 Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. โฆSee details»
Good Therapeutics Being Acquired by Roche for $250M
Sep 13, 2022 The whole Good Therapeutics team will be retained by Bonum. โWith our proven track record in cancer immunotherapy, we are well-positioned to leverage our deep discovery, โฆSee details»
Roche to acquire Good Therapeutics' lead drug program for
Sep 7, 2022 Good Therapeutics previously raised $600,000 in Seed funding, $22 million in a Series A round in 2020 and $10 million in a recent Series B round. Roche Venture Fund is an โฆSee details»
Founder & CEO John Mulligan Shares Good Therapeutics
Jan 31, 2022 We founded Good Therapeutics to create a new kind of context-dependent drug that is active only when and where it is needed. When we started, many natural proteins were โฆSee details»
Good Therapeutics - Contacts, Employees, Board Members
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. ... Chrome Extension. Solutions. Products. โฆSee details»
Good Therapeutics raises $11M to develop โcontext ... - GeekWire
May 21, 2020 Seattle biotech startup Good Therapeutics raised another $11 million to create "context dependent" protein drugs that act only when needed. The 4-year-old. Toggle search โฆSee details»
Good Therapeutics Announces Acquisition of Conditionally Active โฆ
Sep 7, 2022 Good Therapeutics Developing PD-1-regulated IL-2 Drugs Based on Innovative Conditionally Active Drug Technology September 07, 2022 07:00 AM Eastern Daylight TimeSee details»
โThe bar has risenโ: Chinaโs biotech gains push US companies to โฆ
2 days ago Fast-moving research. Todayโs deal boom has roots in efforts by the Chinese government to upgrade the countryโs biotech capabilities by upping investment in โฆSee details»
Series B - Good Therapeutics - 2021-12-30 - Crunchbase
Dec 30, 2021 Good Therapeutics raised $8000000 on 2021-12-30 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. โฆSee details»